犬螺杆菌,肝肠螺杆菌,已经证明了它在人类疾病中的作用,并且随着越来越多的人畜共患潜力被描述,近年来已经被重新讨论。这种病原体的常规微生物学检测是一项艰巨的任务,因为其培养可能会因挑剔的生长而失败。因此,据推测,许多临床实验室对H.canis感染的认识不足。回顾目前所有临床和微生物学文献从以前的相关犬H.canis人类临床病例,主要是菌血症,加上在圣吕克诊所大学观察到的临床病例,已执行。犬H.canis的临床特征报告显示,89%的病例存在潜在的临床状况,83%的菌血症,58%的相关发烧,83%的人最近与宠物有密切接触,尤其是狗。10例菌血症患者观察到的微生物学趋势中位数为4天,直至血培养瓶检测阳性,在生长3-4天后,在35-42°C的微需氧气氛下,传代培养物显示出一层薄薄的小菌落,鉴于使用MALDI-TOFMS观察到的困难,需要进行16SrRNA测序的鉴定。观察到青霉素的MIC低,阿莫西林/克拉维酸,碳青霉烯类,和甲硝唑与环丙沙星的高MIC相反。与宠物接触的反复发烧的免疫功能低下患者中,犬H.canis和菌血症的频繁关联。尤其是狗,已确定。考虑到苛刻的增长能力,血液培养的最终鉴定可能不会在7天之前进行。静脉注射头孢曲松,口服多西环素,或甲硝唑已被建议作为有效的治疗选择。
Helicobacter canis, an enterohepatic Helicobacter, has proven its role in human diseases and has been rediscussed in recent years as its zoonotic potential is increasingly described. Routine microbiological detection of this pathogen is a difficult task as its culture may fail due to fastidious growth. It is therefore supposed that many clinical laboratories under-recognize H. canis infections. A
review of all clinical and microbiological literature currently available from previous relevant H. canis human clinical cases, mainly bacteremia, added with a clinical case observed at the Cliniques universitaires Saint-Luc, was performed. Clinical features of H. canis reports show the presence of underlying clinical conditions in 89% of the cases, bacteremia in 83%, associated fever in 58%, and recent close contact with pets in 83%, especially dogs. The observed microbiological trends from 10 cases of bacteremia were a median of 4 days until positive blood culture bottle detection, subcultures showing a thin layer of small colonies under microaerophilic atmosphere at 35-42°C after 3-4 days of growth, and an identification requiring 16S rRNA sequencing given the difficulties observed with MALDI-TOF MS. Low MICs were observed for penicillins, amoxicillin/clavulanic acid, carbapenems, and metronidazole in opposition to high MICs for ciprofloxacin. A frequent association of H. canis and bacteremia in immunocompromised patients with recurrent fever in contact with pets, especially dogs, was identified. Considering the fastidious growing capacities, final identification from blood cultures may not be expected before 7 days. Intravenous ceftriaxone, oral doxycycline, or metronidazole has been suggested as efficient therapeutic choices.